

News Release – For Immediate Release

Date: 31.01.08

Words: 302

Image Attached

-Copy starts-

**Novexin Plans to Changes Name to Expedeon Protein Solutions
To Raise Awareness of Expanding Product Portfolio in New Markets**

Cambridge, UK: Novexin, a company specialising in protein processing and analysis technology, is delighted to announce the company will be changing its name to Expedeon Protein Solutions. The name change, which will be completed by the end of Q1 2008, reflects Novexin's vision for allowing new clients world-wide to rapidly access powerful technology that is already having a significant impact on protein production and analysis in major pharma and biotech companies.

Following an extensive strategic review of the Novexin offering, Expedeon Protein Solutions has been chosen as the name which best fits the changing face of Novexin's business. Expedeon Protein Solutions, signals Novexin's expansion beyond its core NVoy novel polymer technology, a successful system for enhancing protein stability, solubility and purification, to encompass the increasing commercial profile of its protein assay and detection products. The new business name also demonstrates the company's renewed focus on providing innovative protein technologies to existing and emerging international academic institutes, biotechnology and pharmaceutical companies.

Dr Daniel Jones, CEO of Novexin explained: "To meet the needs of our loyal pharma and biotech client base, as well as match the increase in interest in protein therapies in emerging markets such as China and India, we have enhanced our capabilities to create a more robust, highly competitive and fully integrated protein processing and analysis business."

Jones concluded: "This is why we are pleased to be implementing a new name because Expedeon Protein Solutions reflects our commitment to providing simple and elegant solutions for these markets. We look forward to continuing to work with our supportive existing clients and to raising awareness for new international clients of the benefits Expedeon Protein Solutions' excellent technology will bring to their protein based research."

-Ends-

For further information, please contact:

Dr Daniel Jones, Chief Executive Officer, Novexin Ltd, Babraham Research Campus, Babraham, Cambridge, CB22 3AT, UK.

Tel: +44 (0) 1223 496500 **Fax:** +44 (0) 1223 496741

Email: daniel.jones@novexin.com **Website:** www.novexin.com

Editor Contact:

Dr Sue Pearson, International Science Writer, PO Box 170, Hitchin, Hertfordshire SG5 3GD, UK.

Tel/Fax +44 (0) 1462-635327 Email: sue6.pearson@ntlworld.com

Note to Editors

About Novexin

Novexin, (soon to become Expedeon Protein Solutions), is based in Cambridge, UK and is a biotechnology company that is developing and commercialising proprietary protein processing technology originating from the University of Cambridge. This technology, which is commercially available via kits, reagents, licence or Novexin's contract service organisation, addresses the large untapped global need for robust, high-yielding and scalable protein processing techniques. The company is also expanding its product range to introduce products for quicker and simpler protein analysis.

Novexin, a runner-up in the 2003 Cambridge University Entrepreneurs' Business Plan Competition has grown successfully since 2003, using a total investment of less than £1.5 million. The company, which was initially, funded by DTI Research and Development Awards (£35,000 and £200,000) and £400,000 from private investors in 2004 has filed a total of four patent applications. The company secured an additional £1 million in 2005 to commercialise its protein processing technology and has to date sold products to more than 1000 clients in major companies and research institutes world-wide.